Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 172 articles:
HTML format
Text format



Single Articles


    September 2017
  1. OUYANG PY, Xiao Y, You KY, Zhang LN, et al
    Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi.
    Oral Oncol. 2017;72:65-72.
    PubMed     Text format     Abstract available


  2. KRISHNAN AR, Zheng H, Kwok JG, Qu Y, et al
    A comprehensive study of smoking-specific microRNA alterations in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;72:56-64.
    PubMed     Text format     Abstract available


  3. LI K, Yang L, Xin P, Chen Y, et al
    Impact of dose volume parameters and clinical factors on acute radiation oral mucositis for locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemoradiotherapy.
    Oral Oncol. 2017;72:32-37.
    PubMed     Text format     Abstract available


  4. ADKINS D, Ley J, Oppelt P, Wildes TM, et al
    nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2017;72:26-31.
    PubMed     Text format     Abstract available


  5. BROWN T, Banks M, Hughes BGM, Lin C, et al
    Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer.
    Oral Oncol. 2017;72:17-25.
    PubMed     Text format     Abstract available


  6. BROWN T, Banks M, Hughes BGM, Lin C, et al
    Tube feeding during treatment for head and neck cancer - Adherence and patient reported barriers.
    Oral Oncol. 2017;72:140-149.
    PubMed     Text format     Abstract available


  7. ALEXANDER-BRYANT AA, Zhang H, Attaway CC, Pugh W, et al
    Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo.
    Oral Oncol. 2017;72:123-131.
    PubMed     Text format     Abstract available


  8. STOKES WA, Stumpf PK, Jones BL, Blatchford PJ, et al
    Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States.
    Oral Oncol. 2017;72:110-116.
    PubMed     Text format     Abstract available


  9. ALSIDAWI S, Price KA, Chintakuntlawar AV, Westin GF, et al
    Characteristics and long-term outcomes of head and neck squamous cell carcinoma after solid organ transplantation.
    Oral Oncol. 2017;72:104-109.
    PubMed     Text format     Abstract available


    August 2017
  10. SAFIRI S, Ayubi E
    Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease: Methodological issues.
    Oral Oncol. 2017;71:95.
    PubMed     Text format    


  11. MORISADA M, Moore EC, Hodge R, Friedman J, et al
    Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer.
    Oral Oncol. 2017;71:87-94.
    PubMed     Text format     Abstract available


  12. KIM TH, Kim YN, Kim HI, Park SY, et al
    Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma.
    Oral Oncol. 2017;71:81-86.
    PubMed     Text format     Abstract available


  13. ARRIBAS L, Hurtos L, Taberna M, Peiro I, et al
    Nutritional changes in patients with locally advanced head and neck cancer during treatment.
    Oral Oncol. 2017;71:67-74.
    PubMed     Text format     Abstract available


  14. TAO Y, Auperin A, Graff P, Lapeyre M, et al
    Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
    Oral Oncol. 2017;71:61-66.
    PubMed     Text format     Abstract available


  15. KITANI Y, Kubota A, Furukawa M, Hori Y, et al
    Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis.
    Oral Oncol. 2017;71:54-59.
    PubMed     Text format     Abstract available


  16. MATOS LL, Dedivitis RA, Kulcsar MAV, de Mello ES, et al
    External validation of the AJCC Cancer Staging Manual, 8th edition, in an independent cohort of oral cancer patients.
    Oral Oncol. 2017;71:47-53.
    PubMed     Text format     Abstract available


  17. MASSA ST, Osazuwa-Peters N, Franco J, Ward GW, et al
    Survival after refusal of surgical treatment for locally advanced laryngeal cancer.
    Oral Oncol. 2017;71:34-40.
    PubMed     Text format     Abstract available


  18. WENDRICH AW, Swartz JE, Bril SI, Wegner I, et al
    Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.
    Oral Oncol. 2017;71:26-33.
    PubMed     Text format     Abstract available


  19. OOFT ML, van Ipenburg JA, Braunius WW, Zuur CI, et al
    Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma.
    Oral Oncol. 2017;71:16-25.
    PubMed     Text format     Abstract available


  20. HINGORANI DV, Lemieux AJ, Acevedo JR, Glasgow HL, et al
    Early detection of squamous cell carcinoma in carcinogen induced oral cancer rodent model by ratiometric activatable cell penetrating peptides.
    Oral Oncol. 2017;71:156-162.
    PubMed     Text format     Abstract available


  21. OU D, Blanchard P, Rosellini S, Levy A, et al
    Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
    Oral Oncol. 2017;71:150-155.
    PubMed     Text format     Abstract available


  22. BRYERE J, Menvielle G, Dejardin O, Launay L, et al
    Neighborhood deprivation and risk of head and neck cancer: A multilevel analysis from France.
    Oral Oncol. 2017;71:144-149.
    PubMed     Text format     Abstract available


  23. PARK YM, Jung CM, Cha D, Kim SH, et al
    The long-term oncological and functional outcomes of transoral robotic surgery in patients with hypopharyngeal cancer.
    Oral Oncol. 2017;71:138-143.
    PubMed     Text format     Abstract available


  24. DONG Y, Ridge JA, Li T, Lango MN, et al
    Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer.
    Oral Oncol. 2017;71:122-128.
    PubMed     Text format     Abstract available


  25. GIULIANI M, Milne R, McQuestion M, Sampson L, et al
    Partner's survivorship care needs: An analysis in head and neck cancer patients.
    Oral Oncol. 2017;71:113-121.
    PubMed     Text format     Abstract available


  26. ANTUNES HS, Herchenhorn D, Small IA, Araujo CMM, et al
    Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis.
    Oral Oncol. 2017;71:11-15.
    PubMed     Text format     Abstract available


  27. CHEN MM, Orosco RK, Harris JP, Porter JB, et al
    Predictors of readmissions after head and neck cancer surgery: A national perspective.
    Oral Oncol. 2017;71:106-112.
    PubMed     Text format     Abstract available


  28. JERZAK KJ, Delos Santos K, Saluja R, Lien K, et al
    A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN).
    Oral Oncol. 2017;71:1-10.
    PubMed     Text format     Abstract available


    July 2017
  29. BAIS MV, Kukuruzinska M, Trackman PC
    Corrigendum to "Orthotopic non-metastatic and metastatic oral cancer mouse models" [Oral Oncol. 51(5) (2015) 476-482].
    Oral Oncol. 2017 Jul 22. pii: S1368-8375(17)30198.
    PubMed     Text format    


  30. CHAN JYW, Chan RCL, Chow VLY, Tsang RKY, et al
    Transoral robotic total laryngopharyngectomy and free jejunal flap reconstruction for hypopharyngeal cancer.
    Oral Oncol. 2017 Jul 15. pii: S1368-8375(17)30187.
    PubMed     Text format     Abstract available


  31. KE LR, Xia WX, Qiu WZ, Huang XJ, et al
    A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2017;70:7-13.
    PubMed     Text format     Abstract available


  32. JI YB, Song CM, Bang HS, Park HJ, et al
    Functional and cosmetic outcomes of robot-assisted neck dissection by a postauricular facelift approach for head and neck cancer.
    Oral Oncol. 2017;70:51-57.
    PubMed     Text format     Abstract available


  33. DE MEULENAERE A, Vermassen T, Aspeslagh S, Huvenne W, et al
    Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;70:34-42.
    PubMed     Text format     Abstract available


  34. ALI J, Sabiha B, Jan HU, Haider SA, et al
    Genetic etiology of oral cancer.
    Oral Oncol. 2017;70:23-28.
    PubMed     Text format     Abstract available


    June 2017
  35. LE QT, Welch JJ, Vermorken JB, Rischin D, et al
    Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG.
    Oral Oncol. 2017 Jun 22. pii: S1368-8375(17)30139.
    PubMed     Text format     Abstract available


  36. XU C, Chen YP, Liu X, Li WF, et al
    Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
    Oral Oncol. 2017;69:99-107.
    PubMed     Text format     Abstract available


  37. AI QY, King AD, Mo FKF, Law BKH, et al
    Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease.
    Oral Oncol. 2017;69:74-79.
    PubMed     Text format     Abstract available


  38. TANG LL, Tang XR, Li WF, Chen L, et al
    The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement.
    Oral Oncol. 2017;69:68-73.
    PubMed     Text format     Abstract available


  39. ADAMI GR, Tang JL, Markiewicz MR
    Improving accuracy of RNA-based diagnosis and prognosis of oral cancer by using noninvasive methods.
    Oral Oncol. 2017;69:62-67.
    PubMed     Text format     Abstract available


  40. LAPRISE C, Madathil SA, Schlecht NF, Castonguay G, et al
    Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study.
    Oral Oncol. 2017;69:56-61.
    PubMed     Text format     Abstract available


  41. STABILE LP, Egloff AM, Gibson MK, Gooding WE, et al
    IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
    Oral Oncol. 2017;69:38-45.
    PubMed     Text format     Abstract available


  42. WU LR, Liu YT, Jiang N, Fan YX, et al
    Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center.
    Oral Oncol. 2017;69:26-32.
    PubMed     Text format     Abstract available


  43. WICHMANN G, Herchenhahn C, Boehm A, Mozet C, et al
    HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients.
    Oral Oncol. 2017;69:115-127.
    PubMed     Text format     Abstract available


  44. CHEN CC, Lin JC, Chen KW
    Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
    Oral Oncol. 2017;69:11-14.
    PubMed     Text format     Abstract available


    May 2017
  45. CHOUGULE A, Patil VM, Noronha V, Joshi A, et al
    Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.
    Oral Oncol. 2017 May 22. pii: S1368-8375(17)30115.
    PubMed     Text format    


  46. SHAIKH MH, Clarke DTW, Johnson NW, McMillan NAJ, et al
    Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?
    Oral Oncol. 2017;68:9-19.
    PubMed     Text format     Abstract available


  47. NOIJ DP, Martens RM, Marcus JT, de Bree R, et al
    Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: A systematic review of the diagnostic and prognostic value.
    Oral Oncol. 2017;68:81-91.
    PubMed     Text format     Abstract available


  48. ZHAI RP, Kong FF, Du CR, Hu CS, et al
    Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study.
    Oral Oncol. 2017;68:44-49.
    PubMed     Text format     Abstract available


  49. HUANG TT, Huang JS, Wang YY, Chen KC, et al
    Novel quantitative analysis of autofluorescence images for oral cancer screening.
    Oral Oncol. 2017;68:20-26.
    PubMed     Text format     Abstract available


    April 2017
  50. RUEDA A, Giralt J, Manos M, Lozano A, et al
    Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2).
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30087.
    PubMed     Text format     Abstract available


  51. MANOS M, Giralt J, Rueda A, Cabrera J, et al
    Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30088.
    PubMed     Text format     Abstract available


  52. AYUBI E, Safiri S
    Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis: Comment on data sparsity.
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30086.
    PubMed     Text format    


  53. YANG Q, Zou X, You R, Liu YP, et al
    Proposal for a new risk classification system for nasopharyngeal carcinoma patients with post-radiation nasopharyngeal necrosis.
    Oral Oncol. 2017;67:83-88.
    PubMed     Text format     Abstract available


  54. BORCHIELLINI D, Etienne-Grimaldi MC, Bensadoun RJ, Benezery K, et al
    Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.
    Oral Oncol. 2017;67:70-76.
    PubMed     Text format     Abstract available


  55. HANNA GJ, Liu H, Jones RE, Bacay AF, et al
    Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:61-69.
    PubMed     Text format     Abstract available


  56. OUYANG PY, Zhang LN, Xiao Y, Lan XW, et al
    Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;67:37-45.
    PubMed     Text format     Abstract available


  57. PEREZ CA, Wu X, Amsbaugh MJ, Gosain R, et al
    High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:24-28.
    PubMed     Text format     Abstract available


  58. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;67:183-191.
    PubMed     Text format     Abstract available


  59. POLESEL J, Furlan C, Birri S, Giacomarra V, et al
    The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy.
    Oral Oncol. 2017;67:175-182.
    PubMed     Text format     Abstract available


  60. XIA WX, Liang H, Lv X, Wang L, et al
    Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis.
    Oral Oncol. 2017;67:167-174.
    PubMed     Text format     Abstract available


  61. CHAU L, Jabara JT, Lai W, Svider PF, et al
    Topical agents for oral cancer chemoprevention: A systematic review of the literature.
    Oral Oncol. 2017;67:153-159.
    PubMed     Text format     Abstract available


  62. DE FELICE F, Guerrero Urbano T
    New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
    Oral Oncol. 2017;67:119-123.
    PubMed     Text format     Abstract available


  63. KADLETZ L, Thurnher D, Wiebringhaus R, Erovic BM, et al
    Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;67:109-118.
    PubMed     Text format     Abstract available


  64. KOFLER B, Borena W, Manzl C, Dudas J, et al
    Sensitivity of tumor surface brushings to detect human papilloma virus DNA in head and neck cancer.
    Oral Oncol. 2017;67:103-108.
    PubMed     Text format     Abstract available


  65. RASTOGI M, Sapru S, Gupta P, Gandhi AK, et al
    Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.
    Oral Oncol. 2017;67:10-16.
    PubMed     Text format     Abstract available


  66. HAMOIR M, Holvoet E, Ambroise J, Lengele B, et al
    Salvage surgery in recurrent head and neck squamous cell carcinoma: Oncologic outcome and predictors of disease free survival.
    Oral Oncol. 2017;67:1-9.
    PubMed     Text format     Abstract available


    March 2017
  67. BOONSTRA MC, Van Driel PB, Keereweer S, Prevoo HA, et al
    Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer.
    Oral Oncol. 2017;66:1-8.
    PubMed     Text format     Abstract available


    February 2017
  68. PARK JS, Chang JW, Liu L, Jung SN, et al
    Clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma.
    Oral Oncol. 2017 Feb 17. pii: S1368-8375(17)30028.
    PubMed     Text format     Abstract available


  69. BELL RB, Gough MJ, Seung SK, Jutric Z, et al
    Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].
    Oral Oncol. 2017 Feb 12. pii: S1368-8375(17)30021.
    PubMed     Text format    


  70. CAO W, Liu JN, Liu Z, Wang X, et al
    A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2017;65:94-101.
    PubMed     Text format     Abstract available


  71. MASSA ST, Osazuwa-Peters N, Christopher KM, Arnold LD, et al
    Competing causes of death in the head and neck cancer population.
    Oral Oncol. 2017;65:8-15.
    PubMed     Text format     Abstract available


  72. RIEKE K, Schmid KK, Lydiatt W, Houfek J, et al
    Depression and survival in head and neck cancer patients.
    Oral Oncol. 2017;65:76-82.
    PubMed     Text format     Abstract available


  73. KRISHNAN AR, Korrapati A, Zou AE, Qu Y, et al
    Smoking status regulates a novel panel of PIWI-interacting RNAs in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;65:68-75.
    PubMed     Text format     Abstract available


  74. O'BRIEN KM, Timmons A, Butow P, Gooberman-Hill R, et al
    Associations between neighbourhood support and financial burden with unmet needs of head and neck cancer survivors.
    Oral Oncol. 2017;65:57-64.
    PubMed     Text format     Abstract available


  75. KAINULAINEN S, Tornwall J, Koivusalo AM, Suominen AL, et al
    Dexamethasone in head and neck cancer patients with microvascular reconstruction: No benefit, more complications.
    Oral Oncol. 2017;65:45-50.
    PubMed     Text format     Abstract available


    January 2017
  76. LUCHINI C, Veronese N
    The importance of extranodal extension in metastatic head and neck squamous cell carcinoma, in the light of the new AJCC cancer staging system.
    Oral Oncol. 2017 Jan 9. pii: S1368-8375(16)30279.
    PubMed     Text format    


  77. SWICK AD, Stein AP, McCulloch TM, Hartig GK, et al
    Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts.
    Oral Oncol. 2017;64:65-72.
    PubMed     Text format     Abstract available


  78. BRAVI F, Polesel J, Garavello W, Serraino D, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and head and neck cancers risk.
    Oral Oncol. 2017;64:59-64.
    PubMed     Text format     Abstract available


  79. VAN DEUDEKOM FJ, Schimberg AS, Kallenberg MH, Slingerland M, et al
    Functional and cognitive impairment, social environment, frailty and adverse health outcomes in older patients with head and neck cancer, a systematic review.
    Oral Oncol. 2017;64:27-36.
    PubMed     Text format     Abstract available


  80. LIU YC, Wang WY, Twu CW, Jiang RS, et al
    Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients.
    Oral Oncol. 2017;64:15-21.
    PubMed     Text format     Abstract available


  81. MORONEY LB, Helios J, Ward EC, Crombie J, et al
    Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT+/-concurrent chemotherapy.
    Oral Oncol. 2017;64:1-8.
    PubMed     Text format     Abstract available


    December 2016
  82. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Corrigendum to 'Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents' [Oral Oncol. 62 (2016) 20-27].
    Oral Oncol. 2016 Dec 30. pii: S1368-8375(16)30270.
    PubMed     Text format    


  83. GALVAO-MOREIRA LV, da Cruz MC
    Corrigendum to "Oral microbiome, periodontitis and risk of head and neck cancer" [Oral Oncol. 53 (2016) 17-19].
    Oral Oncol. 2016 Dec 23. pii: S1368-8375(16)30266.
    PubMed     Text format    


  84. LI YJ, Lai WT, Chang CC, Kuo MY, et al
    Ataxia-telangiectasia mutated interactor regulates head and neck cancer metastasis via KRas expression.
    Oral Oncol. 2016 Dec 21. pii: S1368-8375(16)30214.
    PubMed     Text format     Abstract available


  85. YAMAMOTO VN, Thylur DS, Bauschard M, Schmale I, et al
    Overcoming radioresistance in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;63:44-51.
    PubMed     Text format     Abstract available


  86. FERNANDEZ-MATEOS J, Seijas-Tamayo R, Mesia R, Taberna M, et al
    Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Oral Oncol. 2016;63:38-43.
    PubMed     Text format     Abstract available


  87. INGLEHART RC, Taberna M, Pickard RK, Hoff M, et al
    HPV knowledge gaps and information seeking by oral cancer patients.
    Oral Oncol. 2016;63:23-29.
    PubMed     Text format     Abstract available


  88. PATIL V, Joshi A, Noronha V, Deodhar J, et al
    Expectations and preferences for palliative chemotherapy in head and neck cancers patients.
    Oral Oncol. 2016;63:10-15.
    PubMed     Text format     Abstract available


    November 2016
  89. DASTE A, de Mones E, Digue L, Francois L, et al
    Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.
    Oral Oncol. 2016 Nov 3. pii: S1368-8375(16)30196.
    PubMed     Text format    


  90. PENG H, Chen L, Li WF, Zhang Y, et al
    Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis.
    Oral Oncol. 2016;62:78-84.
    PubMed     Text format     Abstract available


  91. LIU L, Chang JW, Jung SN, Park HS, et al
    Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma.
    Oral Oncol. 2016;62:72-77.
    PubMed     Text format     Abstract available


  92. MERMOD M, Tolstonog G, Simon C, Monnier Y, et al
    Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2016;62:60-71.
    PubMed     Text format     Abstract available


  93. DEL BARCO MORILLO E, Mesia R, Adansa Klain JC, Vazquez Fernandez S, et al
    Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
    Oral Oncol. 2016;62:54-59.
    PubMed     Text format     Abstract available


  94. BLANCHARD P, Volk RJ, Ringash J, Peterson SK, et al
    Assessing head and neck cancer patient preferences and expectations: A systematic review.
    Oral Oncol. 2016;62:44-53.
    PubMed     Text format     Abstract available


  95. CHENG SJ, Chang CF, Lee JJ, Chen HM, et al
    Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer.
    Oral Oncol. 2016;62:34-43.
    PubMed     Text format     Abstract available


  96. SWARTZ JE, Pothen AJ, Wegner I, Smid EJ, et al
    Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients.
    Oral Oncol. 2016;62:28-33.
    PubMed     Text format     Abstract available


  97. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents.
    Oral Oncol. 2016;62:20-27.
    PubMed     Text format     Abstract available


  98. KUO TJ, Chu CH, Tang PL, Lai YC, et al
    Effects of geographic area and socioeconomic status in Taiwan on survival rates of head and neck cancer patients after radiotherapy.
    Oral Oncol. 2016;62:136-138.
    PubMed     Text format    


  99. NAIK PP, Das DN, Panda PK, Mukhopadhyay S, et al
    Implications of cancer stem cells in developing therapeutic resistance in oral cancer.
    Oral Oncol. 2016;62:122-135.
    PubMed     Text format     Abstract available


  100. OU D, Blanchard P, El Khoury C, De Felice F, et al
    Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
    Oral Oncol. 2016;62:114-121.
    PubMed     Text format     Abstract available


  101. LIM YC, Liu L, Chang JW, Koo BS, et al
    Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis.
    Oral Oncol. 2016;62:109-113.
    PubMed     Text format     Abstract available


  102. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas.
    Oral Oncol. 2016;62:1-10.
    PubMed     Text format     Abstract available


    October 2016
  103. EDER-CZEMBIREK C, Czembirek C, Selzer E
    Erratum to "Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival" [Oral Oncol. 60 (2016) 1-7].
    Oral Oncol. 2016 Oct 31. pii: S1368-8375(16)30192.
    PubMed     Text format    


  104. LOW GM, Thylur DS, Yamamoto V, Sinha UK, et al
    Erratum to "The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma" [Oral Oncol. 61 (2016) 27-30].
    Oral Oncol. 2016 Oct 31. pii: S1368-8375(16)30193.
    PubMed     Text format    


  105. BAXI SS, Dunn LA, Burtness BA
    Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.
    Oral Oncol. 2016 Oct 21. pii: S1368-8375(16)30182.
    PubMed     Text format    


  106. ZOLKIND P, Dunn GP, Lin T, Griffith M, et al
    Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
    Oral Oncol. 2016 Oct 14. pii: S1368-8375(16)30175.
    PubMed     Text format     Abstract available


  107. MATHIALAGAN A, Verma RK, Panda NK
    Comparison of spinal accessory dysfunction following neck dissection with harmonic scalpel and electrocautery - A randomized study.
    Oral Oncol. 2016;61:142-5.
    PubMed     Text format     Abstract available


  108. ADHAULIYA N, Kalappanavar AN, Ali IM, Annigeri RG, et al
    Autophagy: A boon or bane in oral cancer.
    Oral Oncol. 2016;61:120-6.
    PubMed     Text format     Abstract available


  109. DIVI V, Tao L, Whittemore A, Oakley-Girvan I, et al
    Geographic variation in Medicare treatment costs and outcomes for advanced head and neck cancer.
    Oral Oncol. 2016;61:83-8.
    PubMed     Text format     Abstract available


  110. HAGEDOORN P, Vandenheede H, Vanthomme K, Willaert D, et al
    A cohort study into head and neck cancer mortality in Belgium (2001-11): Are individual socioeconomic differences conditional on area deprivation?
    Oral Oncol. 2016;61:76-82.
    PubMed     Text format     Abstract available


  111. PURKAYASTHA M, McMahon AD, Gibson J, Conway DI, et al
    Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975-2012) - A socioeconomic perspective.
    Oral Oncol. 2016;61:70-5.
    PubMed     Text format     Abstract available


  112. CHAMCHOD S, Fuller CD, Mohamed AS, Grossberg A, et al
    Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement.
    Oral Oncol. 2016;61:62-9.
    PubMed     Text format     Abstract available


  113. FIGUEIREDO RA, Weiderpass E, Tajara EH, Strom P, et al
    Diabetes mellitus, metformin and head and neck cancer.
    Oral Oncol. 2016;61:47-54.
    PubMed     Text format     Abstract available


  114. WIRTH LJ, Dakhil S, Kornek G, Axelrod R, et al
    PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016;61:31-40.
    PubMed     Text format     Abstract available


  115. LOW GM, Thylur DS, N Yamamoto V, Sinha UK, et al
    The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;61:27-30.
    PubMed     Text format     Abstract available


  116. SINEVICI N, O'sullivan J
    Oral cancer: Deregulated molecular events and their use as biomarkers.
    Oral Oncol. 2016;61:12-8.
    PubMed     Text format     Abstract available


  117. SCHMIDT H, Kulasinghe A, Kenny L, Punyadeera C, et al
    The development of a liquid biopsy for head and neck cancers.
    Oral Oncol. 2016;61:8-11.
    PubMed     Text format     Abstract available


  118. ADKINS D, Ley J, Michel L, Wildes TM, et al
    nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
    Oral Oncol. 2016;61:1-7.
    PubMed     Text format     Abstract available


    September 2016
  119. RANCOULE C, Vallard A, Espenel S, Guy JB, et al
    Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.
    Oral Oncol. 2016 Sep 9. pii: S1368-8375(16)30154.
    PubMed     Text format     Abstract available


  120. BRYAN BELL R, Gough MJ, Seung SK, Jutric Z, et al
    Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.
    Oral Oncol. 2016 Sep 7. pii: S1368-8375(16)30149.
    PubMed     Text format     Abstract available


  121. MANSHA MA, Abbasi AN, Ali N, Hafiz A, et al
    Correspondence on review article published in Oral Oncology (Vol. 59, August 2016): "Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer."
    Oral Oncol. 2016 Sep 6. pii: S1368-8375(16)30152.
    PubMed     Text format    


  122. LIN Y, Mallen-St Clair J, Wang G, Luo J, et al
    p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;60:81-9.
    PubMed     Text format     Abstract available


  123. LEE JY, Suresh K, Nguyen R, Sapir E, et al
    Predictors of severe long-term toxicity after re-irradiation for head and neck cancer.
    Oral Oncol. 2016;60:32-40.
    PubMed     Text format     Abstract available


  124. MADATHIL SA, Rousseau MC, Wynant W, Schlecht NF, et al
    Nonlinear association between betel quid chewing and oral cancer: Implications for prevention.
    Oral Oncol. 2016;60:25-31.
    PubMed     Text format     Abstract available


  125. LU L, Li J, Zhao C, Xue W, et al
    Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma.
    Oral Oncol. 2016;60:18-24.
    PubMed     Text format     Abstract available


  126. PANDA S, Padhiary SK, Routray S
    Chemokines accentuating protumoral activities in oral cancer microenvironment possess an imperious stratagem for therapeutic resolutions.
    Oral Oncol. 2016;60:8-17.
    PubMed     Text format     Abstract available


  127. CHRISTINA EC, Cornelia C, Edgar S
    Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival.
    Oral Oncol. 2016;60:1-7.
    PubMed     Text format     Abstract available


    August 2016
  128. DASTE A, de Mones E, Dupin C, Francois L, et al
    m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature.
    Oral Oncol. 2016 Aug 30. pii: S1368-8375(16)30136.
    PubMed     Text format    


  129. SZTURZ P, Faivre S
    Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.
    Oral Oncol. 2016 Aug 28. pii: S1368-8375(16)30135.
    PubMed     Text format    


  130. PAI SI, Zandberg DP, Strome SE
    The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.
    Oral Oncol. 2016 Aug 5. pii: S1368-8375(16)30119.
    PubMed     Text format     Abstract available


  131. LICITRA L, Keilholz U, Tahara M, Lin JC, et al
    Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer.
    Oral Oncol. 2016;59:73-9.
    PubMed     Text format     Abstract available


  132. RADES D, Seidl D, Janssen S, Bajrovic A, et al
    Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?
    Oral Oncol. 2016;59:67-72.
    PubMed     Text format     Abstract available


  133. NOHATA N, Abba MC, Gutkind JS
    Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection.
    Oral Oncol. 2016;59:58-66.
    PubMed     Text format     Abstract available


  134. OU D, Levy A, Blanchard P, Nguyen F, et al
    Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Oral Oncol. 2016;59:50-7.
    PubMed     Text format     Abstract available


  135. OOSTING SF, Chen TW, Huang SH, Wang L, et al
    A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer.
    Oral Oncol. 2016;59:43-9.
    PubMed     Text format     Abstract available


  136. PRINCE ME, Zhou L, Moyer JS, Tao H, et al
    Evaluation of the immunogenicity of ALDH(high) human head and neck squamous cell carcinoma cancer stem cells in vitro.
    Oral Oncol. 2016;59:30-42.
    PubMed     Text format     Abstract available


    July 2016
  137. TERENZI V, Cassoni A, Della Monaca M, Priore P, et al
    Oral cancer during pregnancy.
    Oral Oncol. 2016 Jul 2. pii: S1368-8375(16)30092.
    PubMed     Text format    


  138. MICHEL L, Ley J, Wildes TM, Schaffer A, et al
    Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2016;58:41-8.
    PubMed     Text format     Abstract available


  139. WANG K, Amdur RJ, Mendenhall WM, Green R, et al
    Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life.
    Oral Oncol. 2016;58:21-6.
    PubMed     Text format     Abstract available


  140. SUROV A, Stumpp P, Meyer HJ, Gawlitza M, et al
    Simultaneous (18)F-FDG-PET/MRI: Associations between diffusion, glucose metabolism and histopathological parameters in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2016;58:14-20.
    PubMed     Text format     Abstract available


    June 2016
  141. SZTURZ P, Raymond E, Faivre S
    c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside.
    Oral Oncol. 2016 Jun 11. pii: S1368-8375(16)30063.
    PubMed     Text format    


  142. KUO TJ, Ko WT, Chang YC, Lai YC, et al
    Risk of osteoradionecrosis in head and neck cancers: Comparison between oral and non-oral cancers.
    Oral Oncol. 2016 Jun 10. pii: S1368-8375(16)30064.
    PubMed     Text format    


  143. RADES D, Seidl D, Janssen S, Bajrovic A, et al
    Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
    Oral Oncol. 2016;57:40-5.
    PubMed     Text format     Abstract available


  144. IQBAL H, Pan Q
    Image guided surgery in the management of head and neck cancer.
    Oral Oncol. 2016;57:32-9.
    PubMed     Text format     Abstract available


  145. RANSOHOFF A, Wood D, Solomon Henry A, Divi V, et al
    Third party assessment of resection margin status in head and neck cancer.
    Oral Oncol. 2016;57:27-31.
    PubMed     Text format     Abstract available


  146. WARD MC, Adelstein DJ, Bhateja P, Nwizu TI, et al
    Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11.
    Oral Oncol. 2016;57:21-6.
    PubMed     Text format     Abstract available


    May 2016
  147. T PARSONS J, D Greene B
    Induction chemotherapy for head and neck squamous cell carcinoma.
    Oral Oncol. 2016 May 30. pii: S1368-8375(16)30052.
    PubMed     Text format    


  148. UPPALURI R, Bell RB, Sunwoo JB
    Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches.
    Oral Oncol. 2016 May 26. pii: S1368-8375(16)30050.
    PubMed     Text format    


  149. DAVIS RJ, Van Waes C, Allen CT
    Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
    Oral Oncol. 2016 May 20. pii: S1368-8375(16)30045.
    PubMed     Text format     Abstract available


  150. HASSONA Y, Abu Ghosh M, Abu Ghlassi T, Scully C, et al
    Public engagement with oral cancer on Facebook.
    Oral Oncol. 2016 May 6. pii: S1368-8375(16)30034.
    PubMed     Text format    


  151. FENG Y, Li Y, Zhang Y, Zheng H, et al
    Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2016;56:78-83.
    PubMed     Text format     Abstract available


  152. SHARMA S, Bekelman J, Lin A, Lukens JN, et al
    Clinical impact of prolonged diagnosis to treatment interval (DTI) among patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;56:17-24.
    PubMed     Text format     Abstract available


  153. AMINI A, Jasem J, Jones BL, Robin TP, et al
    Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.
    Oral Oncol. 2016;56:1-7.
    PubMed     Text format     Abstract available


    April 2016
  154. ROOPER LM, Gandhi M, Bishop JA, Westra WH, et al
    RNA in-situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in-situ hybridization.
    Oral Oncol. 2016;55:11-6.
    PubMed     Text format     Abstract available


  155. POLEDNAK AP
    Evidence for a stabilization of incidence rates for base of tongue and tonsil carcinoma in the U.S. white population.
    Oral Oncol. 2016;55:e5-6.
    PubMed     Text format    


  156. KANG H, Kwon M, Park JJ, Kim JP, et al
    Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer.
    Oral Oncol. 2016;55:e7-e10.
    PubMed     Text format    


    March 2016
  157. SEDGHIZADEH PP, Billington WD, Paxton D, Ebeed R, et al
    Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis.
    Oral Oncol. 2016;54:15-27.
    PubMed     Text format     Abstract available


  158. SHER DJ, Schwartz DL, Nedzi L, Khan S, et al
    Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.
    Oral Oncol. 2016;54:58-67.
    PubMed     Text format     Abstract available


  159. OZRETIC L, Wagner S, Huebbers CU, Gattenlohner S, et al
    FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;54:e7-9.
    PubMed     Text format    


    February 2016
  160. YIN ZZ, Gao L, Luo JW, Yi JL, et al
    Long-term outcomes of patients with esthesioneuroblastomas: A cohort from a single institution.
    Oral Oncol. 2016;53:48-53.
    PubMed     Text format     Abstract available


  161. KHAN Z, Epstein JB, Marur S, Gillespie MB, et al
    Cetuximab activity in dysplastic lesions of the upper aerodigestive tract.
    Oral Oncol. 2016;53:60-6.
    PubMed     Text format     Abstract available


    January 2016
  162. SAMUELS SE, Tao Y, Lyden T, Haxer M, et al
    Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
    Oral Oncol. 2016 Jan 5. pii: S1368-8375(15)00416.
    PubMed     Text format     Abstract available


  163. GUO T, Rettig E, Fakhry C
    Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;52:97-103.
    PubMed     Text format     Abstract available


  164. VAN MONSJOU HS, Schaapveld M, Hamming-Vrieze O, de Boer JP, et al
    Cause-specific excess mortality in patients treated for cancer of the oral cavity and oropharynx: A population-based study.
    Oral Oncol. 2016;52:37-44.
    PubMed     Text format     Abstract available


    December 2015
  165. WOODY NM, Koyfman SA, Xia P, Yu N, et al
    Regional control is preserved after dose de-escalated radiotherapy to involved lymph nodes in HPV positive oropharyngeal cancer.
    Oral Oncol. 2015 Dec 17. pii: S1368-8375(15)00370.
    PubMed     Text format     Abstract available


    October 2015
  166. TAKES RP, Wierzbicka M, D'Souza G, Jackowska J, et al
    HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?
    Oral Oncol. 2015 Oct 28. pii: S1368-8375(15)00355.
    PubMed     Text format     Abstract available


  167. LEE YS, Park JY, Cho KJ, Kim SB, et al
    Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer.
    Oral Oncol. 2015 Oct 13. pii: S1368-8375(15)00331.
    PubMed     Text format     Abstract available


    September 2015
  168. RAMQVIST T, Mints M, Tertipis N, Nasman A, et al
    Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters.
    Oral Oncol. 2015 Sep 25. pii: S1368-8375(15)00327.
    PubMed     Text format     Abstract available


    August 2015
  169. AL TAMIMI AS, Zaheer S, Ng DC, Osmany S, et al
    The incidence and sites of Nasopharyngeal carcinoma (NPC) metastases on FDG PET/CT scans.
    Oral Oncol. 2015 Aug 24. pii: S1368-8375(15)00291.
    PubMed     Text format     Abstract available


  170. ZHANG B, Mo Z, Du W, Wang Y, et al
    Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2015 Aug 18. pii: S1368-8375(15)00295.
    PubMed     Text format     Abstract available


    July 2015
  171. LIU SZ, Zandberg DP, Schumaker LM, Papadimitriou JC, et al
    Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer.
    Oral Oncol. 2015 Jul 13. pii: S1368-8375(15)00263.
    PubMed     Text format     Abstract available


    June 2015
  172. DAHLSTROM KR, Bell D, Hanby D, Li G, et al
    Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior.
    Oral Oncol. 2015 Jun 25. pii: S1368-8375(15)00239.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: